We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.72B
AUM Growth
-$71.4M
Cap. Flow
-$452M
Cap. Flow %
-16.6%
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Avg Time Held
2.6 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
SLN icon
Silence Therapeutics
SLN
+$44.1M
2
KROS icon
Keros Therapeutics
KROS
+$32.8M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$32.2M
4
CI icon
Cigna
CI
+$21.5M
5
IMNM icon
Immunome
IMNM
+$20.5M

Top Sells

Rank Stock Value
1
IMGN icon
Immunogen Inc
IMGN
+$487M
2
RYZB icon
RayzeBio, Inc. Common Stock
RYZB
+$115M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$67.7M
4
KRYS icon
Krystal Biotech
KRYS
+$31.2M
5
CTLT icon
CATALENT, INC.
CTLT
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
2 Industrials 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ANNX icon
26
Annexon
ANNX
$682M
$39.5M 1.45%
5,503,190
– –
2020 Q3
14 quarters
BSX icon
27
Boston Scientific
BSX
$64B
$38.4M 1.41%
560,926
-132,274
-19% -$8.5M
2023 Q1
4 quarters
CLDX icon
28
Celldex Therapeutics
CLDX
$2.27B
$37.6M 1.38%
896,454
-97,349
-10% -$4M
2020 Q2
15 quarters
KROS icon
29
Keros Therapeutics
KROS
$220M
$36.6M 1.34%
+552,506
New +$32.8M
2024 Q1
0 quarters
CTLT icon
30
DELISTED
CATALENT, INC.
CTLT
$35.7M 1.31%
632,464
-468,002
-43% -$25.3M
2023 Q1
4 quarters
IMVT icon
31
Immunovant
IMVT
$5.68B
$31.3M 1.15%
969,621
-7,451
-0.8% -$272K
2022 Q4
5 quarters
REPL icon
32
Replimune Group
REPL
$1.11B
$30.5M 1.12%
3,729,983
-135,275
-3% -$1.11M
2018 Q3
22 quarters
ABT icon
33
Abbott
ABT
$181B
$29.8M 1.09%
262,371
-3,129
-1% -$359K
2023 Q4
1 quarter
IGMS icon
34
DELISTED
IGM Biosciences
IGMS
$29.6M 1.09%
3,072,478
+100,936
+3% +$1.17M
2019 Q3
18 quarters
ALGN icon
35
Align Technology
ALGN
$10.6B
$28.6M 1.05%
87,255
+37,173
+74% +$10.9M
2023 Q4
1 quarter
COGT icon
36
Cogent Biosciences
COGT
$5.12B
$26.6M 0.98%
3,962,602
+1,048,580
+36% +$6.48M
2023 Q2
3 quarters
ETNB icon
37
DELISTED
89bio
ETNB
$26.4M 0.97%
2,264,566
+295,164
+15% +$3.27M
2023 Q1
4 quarters
CI icon
38
Cigna
CI
$79B
$23.8M 0.87%
+65,435
New +$21.5M
2024 Q1
0 quarters
EVH icon
39
Evolent Health
EVH
$551M
$22.3M 0.82%
679,172
-156,365
-19% -$4.99M
2023 Q2
3 quarters
VERV icon
40
DELISTED
Verve Therapeutics
VERV
$21.3M 0.78%
1,604,515
-114,154
-7% -$1.51M
2021 Q2
11 quarters
TRDA icon
41
Entrada Therapeutics
TRDA
$177M
$18.2M 0.67%
1,283,735
– –
2021 Q4
9 quarters
HCA icon
42
HCA Healthcare
HCA
$101B
$17.5M 0.64%
52,487
-13,613
-21% -$4.16M
2023 Q3
2 quarters
ELV icon
43
Elevance Health
ELV
$92.9B
$16.2M 0.59%
31,223
+8,144
+35% +$4.05M
2020 Q4
13 quarters
ARDX icon
44
Ardelyx
ARDX
$844M
$16M 0.59%
+2,194,560
New +$18.8M
2024 Q1
0 quarters
BOLD icon
45
Boundless Bio
BOLD
$54.3M
$15.9M 0.58%
+1,114,034
New +$15.9M
2024 Q1
0 quarters
SYK icon
46
Stryker
SYK
$112B
$15.5M 0.57%
43,246
-9,895
-19% -$3.33M
2022 Q3
6 quarters
GRTS icon
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$14.8M 0.54%
5,755,075
-117,530
-2% -$287K
2018 Q3
22 quarters
PRME icon
48
Prime Medicine
PRME
$655M
$14.5M 0.53%
2,074,350
+750,000
+57% +$5.69M
2022 Q4
5 quarters
ICLR icon
49
Icon
ICLR
$13.5B
$12.4M 0.46%
+36,949
New +$10.9M
2024 Q1
0 quarters
PGNY icon
50
Progyny
PGNY
$2.11B
$12.2M 0.45%
+320,864
New +$12.1M
2024 Q1
0 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2024 Portfolio in Review

As of Q1 2024, Redmile Group held 86 positions worth $2.72B, down 2.6% from $2.8B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $452M in Q1 2024, closing 9 positions and reducing 27 holdings. Its most notable exit was Immunogen Inc, an estimated $487M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Silence Therapeutics worth $43.8M.

  • Redmile Group's largest Q1 2024 buy was Silence Therapeutics: 2,027,669 shares worth $43.8M.
  • Redmile Group added most to Immunome in Q1 2024, an estimated $20.5M increase.
  • Redmile Group's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $31.2M.
  • Redmile Group fully exited Immunogen Inc in Q1 2024, selling an estimated $487M.
  • Redmile Group's ten largest holdings make up 42% of its $2.72B portfolio in Q1 2024.
  • Redmile Group opened 16 new positions and closed 9 in Q1 2024.
  • Redmile Group's portfolio value fell 2.6% quarter-over-quarter to $2.72B.

Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.